Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » 23andMe Makes Changes to API Policy for Third-Party App Developers

23andMe Makes Changes to API Policy for Third-Party App Developers

Aug 24, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Consumer genomics company 23andMe let customers know this week that it will restrict its application programming interface (API) to select third-party apps.

The firm said that in two weeks it would disable other apps' ability to access customers' 23andMe results through its API. In effect, customers that have shared their 23andMe reports with other apps through its API may no longer work.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Paper Gone

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational Biologist James Taylor Dies

Computational biologist James Taylor has died, according to Johns Hopkins University.

Ever Infected

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

PLOS Papers on Hepatocellular Carcinoma Immune Cells, Regulatory Prostate Cancer Risk SNPs, More

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

What's Popular?

In Business News

  1. Thermo Fisher Preliminary Q1 Revenues up 1 to 2 Percent; Firm Withdraws 2020 Guidance

  2. Co-Diagnostics Gets FDA Emergency Use Authorization for Coronavirus Test

  3. BGI, Aid Genomics Partner to Build COVID-19 Testing Lab in Gaza

  4. Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery

  5. LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.